Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNF103-CHMP3 readthrough protein is a naturally occurring human fusion protein, produced by read-through transcription of the adjacent RNF103 (ring finger protein 103) and CHMP3 (charged multivesicular body protein 3) genes[1][3]. This fusion protein contains sequence and likely functional motifs derived from both parental proteins, with CHMP3 being a notable core component of the endosomal sorting required for transport complex III (ESCRT-III)[2][8]. ESCRT-III is essential for the formation of multivesicular bodies (MVBs), sorting of membrane proteins for lysosomal degradation, the terminal events of cytokinesis, and the budding of some enveloped viruses, including HIV-1[2][4][6][8]. Loss or dysregulation of this pathway is associated with diseases such as frontotemporal dementia, amyotrophic lateral sclerosis, cancer (via growth factor receptor regulation), and infection[2][4]. While no approved therapeutics currently target the RNF103-CHMP3 fusion, its function within ESCRT-III marks it as a potential drug target for modulating intracellular trafficking and membrane dynamics in disease contexts[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNF103-CHMP3 readthrough protein (RNF103-CHMP3).